Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06313957
Status:
RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-03-10
Brief Title:
A Study of LUCAR-20SP in Subjects With RelapsedRefractory B-cell Non-Hodgkin Lymphoma
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Study Overview
Official Title:
A Phase I Clinical Study to Evaluate the Safety Tolerability and Efficacy of LUCAR-20SP an Allogenic Chimeric Antigen ReceptorCAR-T Cell Therapy Targeting CD20 in Subjects With RelapsedRefractory B-cell Non-Hodgkin Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective single-arm open-label exploratory clinical study of LUCAR-20SP in adult subjects with relapsedrefractory B-cell non-Hodgkin lymphoma
Detailed Description:
This is a prospective single-arm open-label exploratory clinical study to evaluate the safety tolerability pharmacokinetics and anti-tumor efficacy profiles of LUCAR-20SP an allogenic CAR-T cell therapy in subjects with relapsedrefractory B-cell non-Hodgkin lymphoma Patients who meet the eligibility criteria will receive LUCAR-20SP infusion The study will include the following sequential stages screening pre-treatment lymphodepleting chemotherapy treatment and follow-up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None